1. Home
  2. AYTU vs NXPL Comparison

AYTU vs NXPL Comparison

Compare AYTU & NXPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • NXPL
  • Stock Information
  • Founded
  • AYTU N/A
  • NXPL 1997
  • Country
  • AYTU United States
  • NXPL United States
  • Employees
  • AYTU N/A
  • NXPL N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • NXPL Telecommunications Equipment
  • Sector
  • AYTU Health Care
  • NXPL Telecommunications
  • Exchange
  • AYTU Nasdaq
  • NXPL Nasdaq
  • Market Cap
  • AYTU 19.7M
  • NXPL 17.9M
  • IPO Year
  • AYTU N/A
  • NXPL N/A
  • Fundamental
  • Price
  • AYTU $2.37
  • NXPL $0.80
  • Analyst Decision
  • AYTU Strong Buy
  • NXPL
  • Analyst Count
  • AYTU 2
  • NXPL 0
  • Target Price
  • AYTU $10.00
  • NXPL N/A
  • AVG Volume (30 Days)
  • AYTU 100.5K
  • NXPL 132.4K
  • Earning Date
  • AYTU 11-12-2025
  • NXPL 11-13-2025
  • Dividend Yield
  • AYTU N/A
  • NXPL N/A
  • EPS Growth
  • AYTU N/A
  • NXPL N/A
  • EPS
  • AYTU N/A
  • NXPL N/A
  • Revenue
  • AYTU $81,659,000.00
  • NXPL $58,766,000.00
  • Revenue This Year
  • AYTU N/A
  • NXPL N/A
  • Revenue Next Year
  • AYTU $2.00
  • NXPL N/A
  • P/E Ratio
  • AYTU N/A
  • NXPL N/A
  • Revenue Growth
  • AYTU 0.41
  • NXPL N/A
  • 52 Week Low
  • AYTU $0.95
  • NXPL $0.43
  • 52 Week High
  • AYTU $2.85
  • NXPL $2.30
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 55.75
  • NXPL 56.74
  • Support Level
  • AYTU $2.21
  • NXPL $0.69
  • Resistance Level
  • AYTU $2.58
  • NXPL $0.74
  • Average True Range (ATR)
  • AYTU 0.13
  • NXPL 0.06
  • MACD
  • AYTU 0.01
  • NXPL 0.01
  • Stochastic Oscillator
  • AYTU 48.78
  • NXPL 45.17

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About NXPL NextPlat Corp

NextPlat Corp is an e-commerce and healthcare company. Its e-commerce venues form an effective network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.

Share on Social Networks: